Targovax

Targovax is a Norwegian-based global biotechnology company, dedicated to the design and development of immunotherapy vaccines for patients with cancer.

The company, which was born out of the merger in July 2015 of Targovax and Oncos Therapeutics, presented encouraging Phase I/II results in February 2017 on its prospective targeted immunotherapeutic TG01, in resected pancreatic cancer.

Those results led the company's share price to jump by a third in a day's trading.

Latest Targovax News & Features

Strength of Folfirinox data spells the end for Targovax program

13 June 2018

Chinese investors face cultural barriers in acquiring foreign assets

14 May 2018

Early data indicate efficacy of Targovax immuno-oncology candidate

2 February 2017

Targovax

Latest Targovax News & Features

Today's issue